In vivo real-time fluorescence visualization and brain-targeting mechanisms of lipid nanocarriers with different fatty ester: Oil ratios

Nanomedicine

Volumn 6, Issue 9, 2011, Pages 1545-1559

  Wen, Chih Jen ^a   Yen, Tzu Chen ^a   Al Suwayeh, Saleh A ^b   Chang, Hui Wen ^c   Fang, Jia You ^b,c,d  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

^c CHANG GUNG UNIVERSITY   (Taiwan)

^d CHANG GUNG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

Author keywords

brain targeting; cetyl palmitate; lipid nanocarriers; real time imaging; squalene

Indexed keywords

CATIONIC SURFACTANT; CETYL PALMITATE; DISTEAROYLPHOSPHATIDYLETHANOLAMINE; FATTY ACID ESTER; FORESTALL; GLYCEROL OLEATE; LIPID; MACROGOL DERIVATIVE; NANOCARRIER; NANOPARTICLE; OIL; POLOXAMER; POLYSORBATE 80; SOYAETHYL MORPHOLINIUM ETHOSULFATE; SQUALENE; SULFORHODAMINE B; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BRAIN; BRAIN SLICE; CAVEOLA; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; ENDOCYTOSIS; FLUORESCENCE; FLUORESCENCE MICROSCOPY; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; MALE; NEUROIMAGING; NONHUMAN; PARTICLE SIZE; PINOCYTOSIS; PRIORITY JOURNAL; RAT; SURFACE PROPERTY; SUSTAINED DRUG RELEASE; ZETA POTENTIAL;

ANIMALS; BRAIN; CELL LINE; DRUG CARRIERS; LIPIDS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; NANOPARTICLES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 81255195832     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.11.46     Document Type: Article

References (52)

1. Kaur IP, Bhandari R, Bhandari S, Kakkar V. Potential of solid lipid nanoparticles in brain targeting. J. Control. Release 127, 97-109 (2008).
2. Kabanov AV, Batrakova EV. New technologies for drug delivery across the blood brain barrier. Curr. Pharm. Des. 10, 1355-1363 (2004).
3. Krauze MT, Forsayeth J, Park JW, Bankiewicz KS. Real-time imaging and quantification of brain delivery of liposomes. Pharm. Res. 23, 2493-2504 (2006).
4. Jallouli Y, Paillard A, Chang J, Sevin E, Betbeder D. Influence of surface charge and inner composition of porous nanoparticles to cross blood-brain barrier in vitro. Int. J. Pharm. 244, 103-109 (2007).
5. Parveen S, Sahoo SK. Polymeric nanoparticles for cancer therapy. J. Drug Target. 16, 108-123 (2008).
6. Yang SC, Lu LF, Cai Y, Zhu JB, Liang BW, Yang CZ. Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. J. Control. Release 59, 299-307 (1999).
7. Baspinar Y, Keck CM, Borchert HH. Development of a positively charged prednicarbate nanoemulsion. Int. J. Pharm. 383, 201-208 (2010).
8. Huang ZR, Hua SC, Yang YL, Fang JY. Development and evaluation of lipid nanoparticles for camptothecin delivery: a comparison of solid lipid nanoparticles, nanostructured lipid carriers, and lipid emulsion. Acta Pharmacol. Sin. 29, 1094-1102 (2008).
9. Wang JJ, Sung KC, Hu OYP, Yeh CH, Fang JY. Submicron lipid emulsion as a drug delivery system for nalbuphine and its prodrugs. J. Control. Release 115, 140-149 (2006).
10. Béduneau A, Hindré F, Clavreul A, Leroux J, Saulinier P, Benoit J. Brain targeting using novel lipid nanovectors. J. Control. Release 126, 44-49 (2008).
11. Qin Y, Fan W, Chen H et al. In vitro and in vivo investigation of glucose-mediated brain-targeting liposomes. J. Drug Target. 18, 536-549 (2010).
12. Müller RH, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy: rationale for development and what we can expect for the future. Adv. Drug Deliv. Rev. 47, 3-19 (2001).
13. Vérant P, Richard C, Serduc R, Vial JC, van der Sanden B. In vivo staining of neocortical astrocytes via the cerebral microcirculation using sulforhodamine B. J. Biomed. Opt. 13, 064028 (2008).
14. Wilson B, Samanta MK, Santhi K, Kumar KPS, Paramakrishnan N, Suresh B. Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer's disease. Brain Res. 1200, 159-168 (2008).
15. Wang JJ, Liu KS, Sung KC, Tsai CY, Fang JY. Lipid nanoparticles with different oil/fatty ester ratios as carriers of buprenorphine and its prodrugs for injection. Eur. J. Pharm. Sci. 38, 138-146 (2009).
16. Wang JX, Sun X, Zhang ZR. Enhanced brain targeting by synthesis of 3',5'-dioctanoyl-5- fluoro-2'-deoxyuridine and incorporation into solid lipid nanoparticles. Eur. J. Pharm. Biopharm. 54, 285-290 (2002).
17. Esposito E, Fantin M, Marti M et al. Solid lipid nanoparticles as delivery systems for bromocriptine. Pharm. Res. 25, 1521-1530 (2008).
18. Reimold I, Domke D, Bender J, Seyfried CA, Radunz H, Fricker G. Delivery of nanoparticles to the brain detected by fluorescence microscopy. Eur. J. Pharm. Biopharm. 70, 627-632 (2008).
19. Tosi G, Costantino L, Ruozi B, Forni F, Vandelli MA. Polymeric nanoparticles for the drug delivery to the central nervous system. Expert Opin. Drug Deliv. 5, 155-174 (2008).
20. Wong HL, Bendayan R, Rauth AM, Wu XY. Development of solid lipid nanoparticles containing ionically complexed chemotherapeutic drugs and chemosensitizers. J. Pharm. Sci. 93, 1993-2008 (2004).
21. Schubert MA, Harms M, Müller-Goymann CC. Structural investigations on lipid nanoparticles containing high amounts of lecithin. Eur. J. Pharm. Sci. 27, 226-236 (2006).
22. Lombardi Borgia S, Regehly M et al. Lipid nanoparticles for skin penetration enhancement-correlation to drug localization within the particle matrix as determined by fluorescence and parelectric spectroscopy. J. Control. Release 110, 151-163 (2005).
23. Bunjes H, Koch MHJ, Westesen K. Influence of emulsifiers on the crystallization of solid lipid nanoparticles. J. Pharm. Sci. 92, 1509-1520 (2003).
24. Pardridge WM. Biopharmaceutical drug targeting to the brain. J. Drug Target. 18, 157-167 (2010).
25. Soni V, Kohli DV, Jain SK. Transferrin coupled liposomes as drug delivery carriers for brain targeting of 5-fluorouracil. J. Drug Target. 13, 245-250 (2005).
26. Visser CC, Stevanovic S, Voorwinden LH et al. Targeting liposomes with protein drugs to the blood-brain barrier in vitro. Eur. J. Pharm. Sci. 25, 299-305 (2005).
27. Wang JJ, Liu KS, Sung KC, Tsai CY, Fang JY. Skin permeation of buprenorphine and its ester prodrugs from lipid nanoparticles: lipid emulsion, nanostructured lipid carriers, and solid lipid nanoparticles. J. Microencapsul. 26, 734-747 (2009).
28. Bodor N, Buchwald P. Barriers to remember: brain-targeting chemical delivery systems and Alzheimer's disease. Drug Discov. Today 7, 766-774 (2002).
29. Müller RH, Runge SA, Ravelli V, Thünemann AF, Mehnert W, Souto EB. Cyclosporine-loaded solid lipid nanoparticles (SLN®): drug-lipid physicochemical interactions and characterization of drug incorporation. Eur. J. Pharm. Biopharm. 68, 535-544 (2008).
30. Bodor N, Buchwald P. Recent advances in the brain targeting of neuropharmaceuticals by chemical delivery systems. Adv. Drug Deliv. Rev. 36, 229-254 (1999).
31. Brown RC, Morris AP, O'Neil RG. Tight junction protein expression and barrier properties of immortalized mouse brain microvessel endothelial cells. Brain Res. 1130, 17-30 (2007).
32. Yuan W, Li G, Fu BM. Effect of surface charge of immortalized mouse cerebral endothelial cell monolayer on transport of charged solutes. Ann. Biomed. Engin. 38, 1463-1472 (2010).
33. Parikh T, Bommana MM, Squillante E III. Efficacy of surface charge in targeting pegylated nanoparticles of sulpiride to the brain. Eur. J. Pharm. Biopharm. 74, 442-450 (2010).
34. Chattopadhyay N, Zastre J, Wong HL, Wu XY, Bendayan R. Solid lipid nanoparticles enhance the delivery of the HIV protease inhibitor, atazanavir, by a human brain endothelial cell line. Pharm. Res. 25, 2262-2271 (2008).
35. Hillaireau H, Couvreur P. Nanocarriers' entry into the cell: relevance to drug delivery. Cell. Mol. Life Sci. 66, 2873-2896 (2009).
36. Smith MW, Gumbleton M. Endocytosis at the blood-brain barrier: from basic understanding to drug delivery strategies. J. Drug Target. 14, 191-214 (2006).
37. Maxfield FR, McGraw TE. Endocytic recycling. Nat. Rev. Mol. Cell Biol. 5, 121-132 (2004).
38. Jain KK. Nanobiotechnology-based drug delivery to the central nervous system. Neurodegener. Dis. 4, 287-291 (2007).
39. Xia CF, Boado RJ, Zhang Y, Chu C, Pardridge WM. Intravenous glial-derived neurotrophic factor gene therapy of experimental Parkinson's disease with Trojan horse liposomes and a tyrosine hydroxylase promoter. J. Gene Med. 10, 306-315 (2008).
40. Kim HR, Gil S, Andrieux K et al. Low-density lipoprotein receptor-mediated endocytosis of PEGylated nanoparticles in rat brain endothelial cells. Cell. Mol. Life Sci. 64, 356-364 (2007).
41. Kuo YC, Wang CC. Electrophoresis of human brain microvascular endothelial cells with uptake of cationic solid lipid nanoparticles: effect of surfactant composition. Colloids Surf. B Biointerfaces 76, 286-291 (2010).
42. Bareford LM, Swaan PW. Endocytic mechanisms for targeted drug delivery. Adv. Drug Deliv. Rev. 59, 748-758 (2007).
43. Chang J, Jallouli Y, Kroubi M et al. Characterization of endocytosis of transferrin-coated PLGA nanoparticles by the blood-brain barrier. Int. J. Pharm. 379, 285-292 (2009).
44. Liu Y, Huang R, Han L et al. Brain-targeting gene delivery and cellular internalization mechanisms for modified rabies virus glycoprotein RVG29 nanoparticles. Biomaterials 30, 4195-4202 (2009).
45. Wang Z, Tiruppathi C, Minshall RD, Malik AB. Size and dynamics of caveolae studied using nanoparticles in living endothelial cells. ACS Nano 3, 4110-4116 (2009).
46. Conner SD, Schmid SL. Regulated portals of entry into the cell. Nature 422, 37-44 (2003).
47. Koivusalo M, Welch C, Hayashi H et al. Amiloride inhibits macropinocytosis by lowering submembranous pH and preventing Rac 1 and Cdc42 signaling. J. Cell Biol. 188, 547-563 (2010).
48. Harush-Frenkel O, Rozentur E, Benita S, Altschuler Y. Surface charge of nanoparticles determines their endocytic and transcytotic pathway in polarized MDCK cells. Biomacromolecules 9, 435-443 (2008).
49. Driscoll DF. Lipid injectable emulsions: pharmacoepial and safety issues. Pharm. Res. 23, 1959-1969 (2006).
50. Cury-Boaventura MF, Gorjão R, de Lima TM et al. Toxicity of soybean oil emulsion on human lymphocytes and neutrophils. J. Parenter. Enteral. Nutr. 30, 115-123 (2006).
51. Huang ZR, Lin YK, Fang JY. Biological and pharmacological activities of squalene and related compounds: potential uses in cosmetic dermatology. Molecules 14, 540-554 (2009).
52. Harris JM, Chess RB, Effect of pegylation on pharmaceuticals. Nat. Rev. Drug Discov. 2, 214-221 (2003).